Usha Menon

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8956352/usha-menon-publications-by-year.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66 128 19,208 358 h-index g-index citations papers 23,063 5.96 374 7.1 ext. citations L-index avg, IF ext. papers

#	Paper	IF	Citations
358	Common variants in breast cancer risk loci predispose to distinct tumor subtypes <i>Breast Cancer Research</i> , 2022 , 24, 2	8.3	3
357	Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes <i>EBioMedicine</i> , 2022 , 75, 103802	8.8	2
356	Association of adult attachment with delays in accessing specialist care in women with ovarian cancer <i>Journal of Psychosocial Oncology</i> , 2022 , 1-15	2.8	
355	Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews. <i>Diagnostics</i> , 2022 , 12, 1028	3.8	1
354	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 217-228	4	7
353	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas <i>Journal of Pathology</i> , 2021 ,	9.4	3
352	Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021 ,	3.7	1
351	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. <i>Journal of Medical Genetics</i> , 2021 ,	5.8	5
350	Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021 ,	3.7	1
349	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. <i>Trials</i> , 2021 , 22, 173	2.8	1
348	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. <i>Carcinogenesis</i> , 2021 , 42, 785-793	4.6	1
347	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The,</i> 2021 , 397, 2182-2193	40	68
346	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021 , 108, 1190-1203	11	1
345	Population-based targeted sequencing of 54 candidate genes identifies as a susceptibility gene for high-grade serous ovarian cancer. <i>Journal of Medical Genetics</i> , 2021 , 58, 305-313	5.8	12
344	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 301-308	9.7	3
343	Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021 , 128, 714-726	3.7	6
342	Surgical decision making in premenopausal carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study. <i>Journal of Medical Genetics</i> , 2021 ,	5.8	2

(2020-2021)

341	Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Cancers</i> , 2021 , 13,	6.6	1
340	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021 , 125, 1135-1145	8.7	O
339	Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar. <i>Trials</i> , 2021 , 22, 88	2.8	1
338	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020 , 52, 572-581	36.3	76
337	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. <i>Cancers</i> , 2020 , 12,	6.6	8
336	Prognostic gene expression signature for high-grade serous ovarian cancer. <i>Annals of Oncology</i> , 2020 , 31, 1240-1250	10.3	37
335	Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the @o screen@arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Gynecologic Oncology</i> , 2020 , 158, 316-322	4.9	3
334	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020 , 10, 9688	4.9	2
333	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020 , 26, 5411-5423	12.9	21
332	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020 , 123, 793-802	8.7	16
331	Circulating Fatty Acids and Risk of Coronary Heart Disease and Stroke: Individual Participant Data Meta-Analysis in Up to 16 26 Participants. <i>Journal of the American Heart Association</i> , 2020 , 9, e013131	6	13
330	Ovarian cancer screening: Current status and future directions. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020 , 65, 32-45	4.6	34
329	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. <i>Gynecologic Oncology</i> , 2020 , 158, 702-709	4.9	5
328	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. Journal of the National Cancer Institute, 2020 , 112, 1242-1250	9.7	51
327	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , 2020 , 44, 442-468	2.6	9
326	Agreement between questionnaires and registry data on routes to diagnosis and milestone dates of the cancer diagnostic pathway. <i>Cancer Epidemiology</i> , 2020 , 65, 101690	2.8	7
325	Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS. <i>Diagnostics</i> , 2020 , 10,	3.8	1
324	Improved early detection of ovarian cancer using longitudinal multimarker models. <i>British Journal of Cancer</i> , 2020 , 122, 847-856	8.7	31

323	Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes. <i>BJOG:</i> an International Journal of Obstetrics and Gynaecology, 2020 , 127, 364-375	3.7	23
322	Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. <i>Cancer</i> , 2020 , 126, 725-736	6.4	14
321	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. <i>Cancers</i> , 2020 , 12,	6.6	7
320	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies. <i>European Journal of Epidemiology</i> , 2020 , 35, 1025-1042	12.1	2
319	Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. <i>American Journal of Obstetrics and Gynecology</i> , 2020 , 222, 56.e1-56.e17	6.4	11
318	Serial endometrial thickness and risk of non-endometrial hormone-dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020 , 56, 267-275	5.8	1
317	The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. <i>BMC Gastroenterology</i> , 2020 , 20, 104	3	O
316	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019 , 9, 12524	4.9	2
315	Advanced-stage cancer and time to diagnosis: An International Cancer Benchmarking Partnership (ICBP) cross-sectional study. <i>European Journal of Cancer Care</i> , 2019 , 28, e13100	2.4	21
314	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019 , 32, 1834-1846	9.8	21
313	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019 , 8, 2503-2513	4.8	4
312	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019 , 10, 1741	17.4	47
311	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. <i>Genetics in Medicine</i> , 2019 , 21, 2390-2400	8.1	79
310	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. <i>Cancer Prevention Research</i> , 2019 , 12, 391-400	3.2	12
309	Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019 , 126, 784-794	3.7	18
308	Risk-reducing early salpingectomy and delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in women at increased risk: a commentary. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019 , 126, 831-839	3.7	10
307	Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. <i>British Journal of Cancer</i> , 2019 , 121, 483-489	8.7	14
306	Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. <i>PLoS Medicine</i> , 2019 , 16, e1002893	11.6	32

(2018-2019)

305	The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing. <i>Scientific Reports</i> , 2019 , 9, 15787	4.9	5
304	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 38	7.8	12
303	Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP). <i>BMJ Open</i> , 2019 , 9, e025895	3	10
302	Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. <i>Menopause</i> , 2019 , 26, 1100-1009	2.5	13
301	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019 , 104, 21-34	11	363
300	Colorectal cancer ascertainment through cancer registries, hospital episode statistics, and self-reporting compared to confirmation by clinician: A cohort study nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Cancer Epidemiology</i> , 2019 , 58, 167-174	2.8	2
299	A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. <i>International Journal of Cancer</i> , 2019 , 144, 2192-2205	7.5	11
298	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2019 , 48, 795-806	7.8	52
297	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019 , 79, 505-517	10.1	28
296	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 307-320	6.4	14
295	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018 , 118, 1123-1129	8.7	10
294	Current detection rates and time-to-detection of all identifiable carriers in the Greater London population. <i>Journal of Medical Genetics</i> , 2018 , 55, 538-545	5.8	30
293	Ovarian Cancer Prevention and Screening. Obstetrics and Gynecology, 2018, 131, 909-927	4.9	76
292	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 714-725	9.7	92
291	Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. <i>American Journal of Obstetrics and Gynecology</i> , 2018 , 218, 431.e1-431.e12	6.4	23
290	Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 34-42	3.5	17
289	Association between skirt size and chronic liver disease in post-menopausal women: a prospective cohort study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2018 , 18, 409	4.1	
288	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018 , 47, 450-459	7.8	8

287	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. <i>American Journal of Epidemiology</i> , 2018 , 187, 366-377	3.8	7
286	Commentary on changing the risk threshold for surgical prevention of ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018 , 125, 541-544	3.7	7
285	Sonographers&elf-reported visualization of normal postmenopausal ovaries on transvaginal ultrasound is not reliable: results of expert review of archived images from UKCTOCS. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018 , 51, 401-408	5.8	7
284	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018 , 4, 250-26	5 ∮ ·3	38
283	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018 , 13, e0197561	3.7	9
282	Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. <i>Clinical Cancer Research</i> , 2018 , 24, 4726-4733	12.9	26
281	Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis. <i>Oncotarget</i> , 2018 , 9, 17430-17442	3.3	14
280	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	3
279	Ovarian cancer prevention and screening 2018 , 331-348		
278	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018 , 50, 968-978	36.3	101
278 277		36.3 3.6	101
	genes for breast cancer. <i>Nature Genetics</i> , 2018 , 50, 968-978 Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>F1000Research</i> , 2018 ,		
277	genes for breast cancer. <i>Nature Genetics</i> , 2018 , 50, 968-978 Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>F1000Research</i> , 2018 , 7, 1241	3.6	1
277 276	genes for breast cancer. <i>Nature Genetics</i> , 2018 , 50, 968-978 Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>F1000Research</i> , 2018 , 7, 1241 Parenclitic networks for predicting ovarian cancer. <i>Oncotarget</i> , 2018 , 9, 22717-22726 Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking	3.6	1
277 276 275	Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). F1000Research, 2018, 7, 1241 Parenclitic networks for predicting ovarian cancer. Oncotarget, 2018, 9, 22717-22726 Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP). BMJ Open, 2018, 8, e023870 Rural-Urban Disparities in Time to Diagnosis and Treatment for Colorectal and Breast Cancer.	3.6 3.3 3	1 19 24
277 276 275	Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). F1000Research, 2018, 7, 1241 Parenclitic networks for predicting ovarian cancer. Oncotarget, 2018, 9, 22717-22726 Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP). BMJ Open, 2018, 8, e023870 Rural-Urban Disparities in Time to Diagnosis and Treatment for Colorectal and Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1036-1046 A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer.	3.6 3.3 4	1 19 24 30
277 276 275 274 273	Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). F1000Research, 2018, 7, 1241 Parenclitic networks for predicting ovarian cancer. Oncotarget, 2018, 9, 22717-22726 Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP). BMJ Open, 2018, 8, e023870 Rural-Urban Disparities in Time to Diagnosis and Treatment for Colorectal and Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1036-1046 A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer. Biomedical Signal Processing and Control, 2018, 46, 86-93 Steps towards effective gynaecological cancer screening. Nature Reviews Clinical Oncology, 2018,	3.6 3.3 3 4	1 19 24 30

269	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017 , 116, 524-535	8.7	18
268	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. <i>International Journal of Cancer</i> , 2017 , 140, 2422-2435	7.5	18
267	Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus: A Mendelian Randomization Analysis. <i>Circulation</i> , 2017 , 135, 2373-2388	16.7	182
266	The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. <i>British Journal of Cancer</i> , 2017 , 116, 1111-1117	8.7	6
265	Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening. <i>Climacteric</i> , 2017 , 20, 240-247	3.1	60
264	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190
263	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2017 , 116, 1223-1228	8.7	11
262	Change-point of multiple biomarkers in women with ovarian cancer. <i>Biomedical Signal Processing and Control</i> , 2017 , 33, 169-177	4.9	11
261	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017 , 3, e173290	13.4	152
260	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017 , 551, 92-94	50.4	643
260 259	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017 , 551, 92-94 The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. <i>Genome Medicine</i> , 2017 , 9, 116	50.4	6 ₄₃
	The potential of circulating tumor DNA methylation analysis for the early detection and		,,
259	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. <i>Genome Medicine</i> , 2017 , 9, 116 Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis.	14.4	79
259 258	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. <i>Genome Medicine</i> , 2017 , 9, 116 Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. <i>International Journal of Molecular Sciences</i> , 2017 , 18, Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United	14.4	79 19
259 258 257	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. <i>Genome Medicine</i> , 2017 , 9, 116 Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. <i>International Journal of Molecular Sciences</i> , 2017 , 18, Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1411-1420 The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of	6.3	79 19 105
259 258 257 256	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. <i>Genome Medicine</i> , 2017 , 9, 116 Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. <i>International Journal of Molecular Sciences</i> , 2017 , 18, Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1411-1420 The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>British Journal of Cancer</i> , 2017 , 117, 619-627 Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.	14.4 6.3 2.2 8.7	79 19 105
259 258 257 256 255	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. <i>Genome Medicine</i> , 2017 , 9, 116 Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. <i>International Journal of Molecular Sciences</i> , 2017 , 18, Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1411-1420 The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>British Journal of Cancer</i> , 2017 , 117, 619-627 Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5912-5922 Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK	14.4 6.3 2.2 8.7	79 19 105 19

251	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. <i>British Journal of Cancer</i> , 2017 , 117, 666-674	8.7	29
250	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 420-424	4	3
249	Metabolic Profiling of Adiponectin Levels in Adults: Mendelian Randomization Analysis. <i>Circulation: Cardiovascular Genetics</i> , 2017 , 10,		16
248	Methylation patterns in serum DNA for early identification of disseminated breast cancer. <i>Genome Medicine</i> , 2017 , 9, 115	14.4	32
247	Influences on anticipated time to ovarian cancer symptom presentation in women at increased risk compared to population risk of ovarian cancer. <i>BMC Cancer</i> , 2017 , 17, 814	4.8	3
246	Novel risk models for early detection and screening of ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 785-797	3.3	10
245	Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. <i>Oncotarget</i> , 2017 , 8, 3811-3825	3.3	31
244	Germline whole exome sequencing and large-scale replication identifies as a likely high grade serous ovarian cancer susceptibility gene. <i>Oncotarget</i> , 2017 , 8, 50930-50940	3.3	30
243	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401	4.9	15
242	A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. <i>International Journal of Cancer</i> , 2016 , 139, 2646-2654	7.5	6
241	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016 , 6, 1052-	6 7 4·4	104
240	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016 , 7, 12675	17.4	53
239	An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation. <i>BMJ Open</i> , 2016 , 6, e009641	3	26
238	Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Ultrasound in Obstetrics and Gynecology</i> , 2016 , 47, 228-35	5.8	11
237	Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016 , 123, 1012-20	3.7	19
236	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 945-956	40	563
235	Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 201-2	2.2	
234	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 780-90	4	8

(2016-2016)

233	PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	34
232	Importance of serial CA125 measurements over an absolute cut-off value for the detection of asymptomatic ovarian cancer in high-risk patients. <i>International Journal of Gynecology and Obstetrics</i> , 2016 , 133, 239-40	4	2
231	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. <i>Cancer Epidemiology</i> , 2016 , 41, 71-9	2.8	17
230	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 446-54	4	6
229	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. <i>Clinical Cancer Research</i> , 2016 , 22, 1734-1743	12.9	58
228	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	65
227	Evidence of a genetic link between endometriosis and ovarian cancer. <i>Fertility and Sterility</i> , 2016 , 105, 35-43.e1-10	4.8	26
226	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 69097-69110	3.3	4
225	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016 , 7, 72381-72394	3.3	11
224	The double-edged sword of ovarian cancer information for women at increased risk who have previously taken part in screening. <i>Ecancermedicalscience</i> , 2016 , 10, 650	2.7	
223	Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>PLoS ONE</i> , 2016 , 11, e0165539	3.7	6
222	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016 , 45, 884-95	7.8	45
221	Ovarian cancer screening: UKCTOCS trial - Authors@eply. <i>Lancet, The</i> , 2016 , 387, 2603-2604	40	11
220	Benchmarking of surgical complications in gynaecological oncology: prospective multicentre study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016 , 123, 2171-2180	3.7	3
219	Should Opportunistic Bilateral Salpingectomy (OBS) for Prevention of Ovarian Cancer Be Incorporated Into Routine Care or Offered in the Context of a Clinical Trial?. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 31-3	3.5	5
218	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. <i>Obstetrics and Gynecology</i> , 2016 , 127, 828-836	4.9	24
217	Factors Affecting Short-term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer: Population-Based Cohort Analysis of English National Cancer Registration Data. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 56-65	3.5	10
216	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. <i>Human Molecular Genetics</i> , 2016 , 25, 3600-3612	5.6	9

215	Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. <i>Journal of Medical Genetics</i> , 2016 , 53, 472-80	5.8	32
214	Specifying the ovarian cancer risk threshold of @ remenopausal risk-reducing salpingo-oophorectomy G or ovarian cancer prevention: a cost-effectiveness analysis. <i>Journal of Medical Genetics</i> , 2016 , 53, 591-9	5.8	40
213	Refining Ovarian Cancer Test accuracy Scores (ROCkeTS): protocol for a prospective longitudinal test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer. <i>BMJ Open</i> , 2016 , 6, e010333	3	7
212	Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. <i>Nature Communications</i> , 2016 , 7, 11620	17.4	38
211	Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). <i>Steroids</i> , 2016 , 110, 62-69	2.8	11
210	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016 , 135, 741-56	6.3	18
209	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016 , 45, 1619-1630	7.8	77
208	Protein Z: A putative novel biomarker for early detection of ovarian cancer. <i>International Journal of Cancer</i> , 2016 , 138, 2984-92	7.5	35
207	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015 , 47, 164-71	36.3	177
206	Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 379	9.7	112
205	Predictors of complications in gynaecological oncological surgery: a prospective multicentre study (UKGOSOC-UK gynaecological oncology surgical outcomes and complications). <i>British Journal of Cancer</i> , 2015 , 112, 475-84	8.7	31
204	Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 380	9.7	111
203	Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. <i>British Journal of Cancer</i> , 2015 , 113, 268-74	8.7	58
202	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1574-84	4	24
201	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015 , 21, 5264-76	12.9	24
200	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. <i>Gynecologic Oncology</i> , 2015 , 136, 542-8	4.9	12
199	Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2015 , 15, 253	4.1	8
198	Screening for Gynaecological Cancers 2015 , 267-281		

(2015-2015)

19	97	Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2062-71	2.2	133
19	96	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1495-503	6.1	13
19	95	Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study. <i>Menopause</i> , 2015 , 22, 384-90	2.5	18
19	94	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015 , 6, 8234	17.4	40
19	93	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015 , 36, 1341-53	4.6	20
19	92	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015 , 15, 668-79	31.3	581
19	91	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015 , 24, 5955-64	5.6	48
19	90	Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women. <i>Gynecologic Oncology</i> , 2015 , 139, 487-94	4.9	32
18	89	Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. <i>Familial Cancer</i> , 2015 , 14, 521	-330	14
18	88	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2901-7	2.2	200
18	87	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Journal of the National Cancer Institute, 2015 , 107,	9.7	239
18	86	Population distribution of lifetime risk of ovarian cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 671-676	4	67
18	85	Multiprobabilistic prediction in early medical diagnoses. <i>Annals of Mathematics and Artificial Intelligence</i> , 2015 , 74, 203-222	0.8	9
18	84	Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. <i>Journal of Proteomics</i> , 2015 , 113, 400-2	3.9	31
18	83	Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF- B Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. <i>EBioMedicine</i> , 2015 , 2, 1331-9	8.8	41
18	82	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015 , 39, 689-97	2.6	18
18	81	Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset. <i>BioMed Research International</i> , 2015 , 2015, 681416	3	18
18	80	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015 , 10, e0128106	3.7	15

179	Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies. <i>Steroids</i> , 2015 , 99, 49-55	2.8	51
178	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2015 , 24, 3595-607	5.6	32
177	Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. <i>International Journal of Gynecological Cancer</i> , 2015 , 25, 1519-25	3.5	9
176	Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. <i>Clinical Cancer Research</i> , 2015 , 21, 622-31	12.9	124
175	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015 , 2,		22
174	Ovarian cancer screeningcurrent status, future directions. <i>Gynecologic Oncology</i> , 2014 , 132, 490-5	4.9	95
173	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014 , 133, 481-97	6.3	21
172	Adapting the coping in deliberation (CODE) framework: a multi-method approach in the context of familial ovarian cancer risk management. <i>Patient Education and Counseling</i> , 2014 , 97, 200-10	3.1	5
171	Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt431	9.7	149
170	Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , 2014 , 58, 2023-35	5.9	8
169	Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. <i>Proteomics - Clinical Applications</i> , 2014 , 8, 982-93	3.1	34
168	Identifying hopelessness in population research: a validation study of two brief measures of hopelessness. <i>BMJ Open</i> , 2014 , 4, e005093	3	18
167	Mixed methods evaluation of well-being benefits derived from a heritage-in-health intervention with hospital patients. <i>Arts and Health</i> , 2014 , 6, 24-58	1.7	20
166	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. <i>British Journal of Cancer</i> , 2014 , 111, 2297-307	8.7	49
165	Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2014 , 4, e004421	3	11
164	Variation in NF- B signaling pathways and survival in invasive epithelial ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1421-7	4	11
163	Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2014 , 4, e005400	3	6
162	Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS). <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014 , 121, 1071-9	3.7	30

(2013-2014)

Cancer-associated autoantibodies to MUC1 and MUC4a blinded casedontrol study of colorectal cancer in UK collaborative trial of ovarian cancer screening. <i>International Journal of Cancer</i> , 2014 , 134, 2180-88	7.5	45
Risk of ovarian cancer and the NF- B pathway: genetic association with IL1A and TNFSF10. <i>Cancer Research</i> , 2014 , 74, 852-61	10.1	36
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. <i>Cancer Immunology Research</i> , 2014 , 2, 332-40	12.5	20
A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. <i>Genome Medicine</i> , 2014 , 6, 47	14.4	48
Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. <i>BJOG:</i> an International Journal of Obstetrics and Gynaecology, 2014 , 121 Suppl 7, 35-9	3.7	6
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology, The</i> , 2013 , 14, 853-62	21.7	248
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 362-70, 370e1-2	36.3	267
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. <i>Cancer Causes and Control</i> , 2013 , 24, 989-1004	2.8	69
There is a need for routine peritoneal cytology at RRSO. <i>Gynecologic Oncology</i> , 2013 , 128, 149-150	4.9	1
Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013 , 41, 73-9	5.8	15
The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. <i>Lancet Oncology, The</i> , 2013 , 14, 1226-32	21.7	73
Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. <i>Journal of Proteome Research</i> , 2013 , 12, 1408-18	5.6	77
Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. <i>British Journal of Cancer</i> , 2013 , 108, 2045-55	8.7	46
Ovarian cancer symptom awareness and anticipated time to help-seeking for symptoms among UK women. <i>Journal of Family Planning and Reproductive Health Care</i> , 2013 , 39, 163-71		29
Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Ultrasound in Obstetrics and Gynecology</i> , 2013 , 42, 472-7	5.8	9
Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. <i>Journal of Clinical Oncology</i> , 2013 , 31, 49-57	2.2	103
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1677-86	4	53
	cancer in UK collaborative trial of ovarian cancer screening. <i>International Journal of Cancer</i> , 2014, 134, 2180-88 Risk of ovarian cancer and the NF-B pathway: genetic association with IL1A and TNFSF10. <i>Cancer Research</i> , 2014, 74, 852-61 Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. <i>Cancer Immunology Research</i> , 2014, 2, 332-40 A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. <i>Genome Medicine</i> , 2014, 6, 47 Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121 Suppl 7, 35-9 Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , 77e, 2013, 14, 853-62 GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-70, 370e1-2 Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-84, 384e1-2 Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. <i>Cancer Causes and Control</i> , 2013, 24, 989-1004 There is a need for routine peritoneal cytology at RRSO. <i>Gynecologic Oncology</i> , 2013, 128, 149-150 Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 41, 73-9 The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. <i>Lancet Oncology</i> , 77-79, 2013, 14, 1226-32 Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. <i>Journal of Proteome Research</i> , 2013, 12, 1408-18 Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. <i>B</i>	rancer in UK collaborative trial of ovarian cancer screening. International Journal of Cancer, 2014, 134, 2180-88 Risk of ovarian cancer and the NF-B pathway: genetic association with IL1A and TNFSF10. Cancer Research, 2014, 74, 852-61 Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunology Research, 2014, 2, 332-40 A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Medicine, 2014, 6, 47 Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121 Suppl 7, 35-9 Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncology, The, 2013, 14, 853-62 GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-70, 370e1-2 Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-84, 384e1-2 Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes and Cantrol, 2013, 24, 989-1004 There is a need for routine peritoneal cytology at RRSO. Gynecologic Oncology, 2013, 128, 149-150 Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Ultrasound in Obstetrics and Gynecology, 14, 73-9 The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncology, 14, 2013, 14, 1226-32 Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. Journal of Proteome Research, 2013, 12, 1408-18 Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. British Journal of Cancer, 2013, 103,

143	Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 880-90	4	37
142	Heritage, health and well-being: assessing the impact of a heritage focused intervention on health and well-being. <i>International Journal of Heritage Studies</i> , 2013 , 19, 229-242	1.2	28
141	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. <i>Endocrine-Related Cancer</i> , 2013 , 20, 251-62	5.7	135
140	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013 , 4, 1628	17.4	124
139	Concordance of National Cancer Registration with self-reported breast, bowel and lung cancer in England and Wales: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. <i>British Journal of Cancer</i> , 2013 , 109, 2875-9	8.7	8
138	Experience of symptoms indicative of gynaecological cancers in UK women. <i>British Journal of Cancer</i> , 2013 , 109, 882-7	8.7	19
137	Patient-reporting improves estimates of postoperative complication rates: a prospective cohort study in gynaecological oncology. <i>British Journal of Cancer</i> , 2013 , 109, 623-32	8.7	12
136	Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. <i>British Journal of Cancer</i> , 2013 , 108, 107-14	8.7	59
135	Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 987-92	4	20
134	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013 , 4, 1627	17.4	85
133	Screening for gynecological cancers. Expert Review of Obstetrics and Gynecology, 2013, 8, 143-160		1
132	Using Museum Objects to Improve Wellbeing in Mental Health Service Users and Neurological Rehabilitation Clients. <i>British Journal of Occupational Therapy</i> , 2013 , 76, 208-216	1	19
131	MUC16, alias CA125 and ovarian cancer 2013 , 82-93		
130	Screening for ovarian cancer in the general population. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012 , 26, 243-56	4.6	36
129	Withdrawal from familial ovarian cancer screening for surgery: findings from a psychological evaluation study (PsyFOCS). <i>Gynecologic Oncology</i> , 2012 , 124, 158-63	4.9	12
128	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. <i>Lancet Oncology, The</i> , 2012 , 13, 385-94	21.7	612
127	Screening of symptomatic women for ovarian cancer. <i>Lancet Oncology, The</i> , 2012 , 13, e138-9; author reply e139-40	21.7	4
126	Enhancing cancer patient well-being with a nonpharmacological, heritage-focused intervention. Journal of Pain and Symptom Management, 2012 , 44, 731-40	4.8	19

125	Psychological outcomes of familial ovarian cancer screening: no evidence of long-term harm. <i>Gynecologic Oncology</i> , 2012 , 127, 556-63	4.9	16
124	Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). <i>Ultrasound in Obstetrics and Gynecology</i> , 2012 , 40, 338-44	5.8	50
123	Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). <i>Archives of Gynecology and Obstetrics</i> , 2012 , 286, 1555-62	2.5	28
122	Conformal predictors in early diagnostics of ovarian and breast cancers. <i>Progress in Artificial Intelligence</i> , 2012 , 1, 245-257	4	10
121	Preimplantation genetic diagnosis for hereditary cancers. <i>Advances in Experimental Medicine and Biology</i> , 2012 , 732, 103-13	3.6	3
120	Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study. <i>BJOG:</i> an International Journal of Obstetrics and Gynaecology, 2012 , 119, 207-19	3.7	21
119	Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54-65. <i>BJOG: an International Journal of</i>	3.7	87
118	Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012 , 119, 527-36	3.7	42
117	Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 529-36	4	7
116	Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 114-24	9.7	39
115	Quantitative evidence for wellbeing benefits from a heritage-in-health intervention with hospital patients. <i>International Journal of Art Therapy: Inscape</i> , 2012 , 17, 63-79	1.2	20
114	Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. <i>British Journal of Cancer</i> , 2012 , 106, 1910-6	8.7	4
113	Ovarian cancer screening has no effect on disease-specific mortality. <i>Evidence-Based Medicine</i> , 2012 , 17, 47-8		6
112	Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. <i>Endocrine-Related Cancer</i> , 2012 , 19, 137-47	5.7	28
111	Genome-wide association study for ovarian cancer susceptibility using pooled DNA. <i>Twin Research and Human Genetics</i> , 2012 , 15, 615-623	2.2	8
110	Investigating the therapeutic potential of a heritage-object focused intervention: a qualitative study. <i>Journal of Health Psychology</i> , 2012 , 17, 809-20	3.1	18
109	Ovarian and cervical cancer awareness: development of two validated measurement tools. <i>Journal of Family Planning and Reproductive Health Care</i> , 2012 , 38, 167-74		29
108	The UKCTOCS experiencereasons for hope?. <i>International Journal of Gynecological Cancer</i> , 2012 , 22 Suppl 1, S18-20	3.5	19

107	Diathermy-induced injury may affect detection of occult tubal lesions at risk-reducing salpingo-oophorectomy. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 881-8	3.5	5
106	Multiprobabilistic Venn Predictors with Logistic Regression. <i>International Federation for Information Processing</i> , 2012 , 224-233		5
105	Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. <i>Trials</i> , 2011 , 12, 61	2.8	32
104	Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 525-30	5.7	27
103	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. <i>Lancet Oncology, The</i> , 2011 , 12, 38-48	21.7	138
102	Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. <i>PLoS ONE</i> , 2011 , 6, e24987	3.7	41
101	Evaluating the therapeutic effects of museum object handling with hospital patients: A review and initial trial of well-being measures. <i>Journal of Applied Arts and Health</i> , 2011 , 2, 37-56	0.5	13
100	Generic well-being outcomes: towards a conceptual framework for well-being outcomes in museums. <i>Museum Management and Curatorship</i> , 2011 , 26, 237-259	1.3	15
99	Mathematical models to discriminate between benign and malignant adnexal masses: potential diagnostic improvement using ovarian HistoScanning. <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 35-43	3.5	4
98	Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2011 , 118, 814-24	3.7	93
97	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011 , 11, 719-25	31.3	893
96	Psychosocial risk profiles among black male Veterans Administration patients non-adherent with colorectal cancer screening. <i>Psycho-Oncology</i> , 2011 , 20, 1151-60	3.9	4
95	Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. <i>International Journal of Cancer</i> , 2011 , 128, 936-43	7.5	44
94	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2011 , 128, 2063-74	7.5	49
93	The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. <i>Cancer Prevention Research</i> , 2011 , 4, 299-302	3.2	13
92	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. <i>Human Molecular Genetics</i> , 2011 , 20, 2263-72	5.6	18
91	Ovarian cancer screening and mortality. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 1544; author reply 1544-5	27.4	18
90	Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1028-31	4	

(2010-2011)

89	The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. <i>Clinical Cancer Research</i> , 2011 , 17, 3742-50	12.9	45
88	LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. <i>Cancer Research</i> , 2011 , 71, 3896-903	10.1	70
87	MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1793-7	4	18
86	Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011 , 6, e19642	3.7	4
85	Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011 , 6, e20703	3.7	20
84	Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks. <i>Cancer Genomics and Proteomics</i> , 2011 , 8, 289-305	3.3	5
83	Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. <i>British Journal of Cancer</i> , 2010 , 102, 1405-10	8.7	40
82	Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. <i>British Journal of Cancer</i> , 2010 , 103, 454-61	8.7	25
81	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. <i>Nature Genetics</i> , 2010 , 42, 874-9	36.3	277
80	Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1822-30	4	22
79	Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. <i>Clinical Chemistry</i> , 2010 , 56, 262-71	5.5	30
78	Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". <i>PLoS Genetics</i> , 2010 , 6, e1001016	6	42
77	ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 245-50	4	64
76	Development of a multimarker assay for early detection of ovarian cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2159-66	2.2	219
75	Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. <i>Genome Research</i> , 2010 , 20, 440-6	9.7	638
74	Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. <i>Familial Cancer</i> , 2010 , 9, 313-9	3	12
73	Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. <i>Gynecologic Oncology</i> , 2010 , 119, 479-83	4.9	25
72	A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. <i>Proteomics</i> , 2010 , 10, 3388-92	4.8	30

71	A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2010 , 1, 272-7	0.9	7
70	Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 1518-24	3.5	9
69	Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. <i>British Journal of Cancer</i> , 2009 , 101, 1461-8	8.7	34
68	Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. <i>British Journal of Cancer</i> , 2009 , 101, 160-5	8.7	9
67	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. <i>Human Molecular Genetics</i> , 2009 , 18, 2297-304	5.6	37
66	Ovarian cancer. <i>BMJ, The</i> , 2009 , 339, b4650	5.9	4
65	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. <i>Human Molecular Genetics</i> , 2009 , 18, 1869-78	5.6	16
64	Serum Proteomic Abnormality Predating Screen Detection of Ovarian Cancer. <i>Computer Journal</i> , 2009 , 52, 326-333	1.3	12
63	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. <i>International Journal of Cancer</i> , 2009 , 125, 2214-	8 ^{7·5}	50
62	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. <i>Nature Genetics</i> , 2009 , 41, 996-1000	36.3	240
61	Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2009 , 100, 412-20	8.7	42
60	Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. <i>British Journal of Cancer</i> , 2009 , 100, 993-1001	8.7	21
59	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Lancet Oncology, The</i> , 2009 , 10, 327-40	21.7	615
58	Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009 , 21, 31-8	2.4	20
57	An epigenetic signature in peripheral blood predicts active ovarian cancer. <i>PLoS ONE</i> , 2009 , 4, e8274	3.7	245
56	Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 3567-72	4	14
55	Recruitment to multicentre trialslessons from UKCTOCS: descriptive study. <i>BMJ, The</i> , 2008 , 337, a207	'9 5.9	105
54	Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. <i>PLoS ONE</i> , 2008 , 3, e2656	3.7	116

(2005-2008)

53	Consortium analysis of 7 candidate SNPs for ovarian cancer. <i>International Journal of Cancer</i> , 2008 , 123, 380-388	7.5	66	
52	Cancer survivors information seeking behaviors: a comparison of survivors who do and do not seek information about cancer. <i>Patient Education and Counseling</i> , 2007 , 65, 342-50	3.1	161	
51	Serum peptide profiling using MALDI mass spectrometry: avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology. <i>Proteomics</i> , 2007 , 7 Suppl 1, 77-89	4.8	49	
50	Screening practices in cancer survivors. <i>Journal of Cancer Survivorship</i> , 2007 , 1, 17-26	5.1	46	
49	Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. <i>Clinical Chemistry</i> , 2007 , 53, 645-56	5.5	121	
48	Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. <i>Human Reproduction</i> , 2007 , 22, 1573-7	5.7	105	
47	Health behaviors in cancer survivors. <i>Oncology Nursing Forum</i> , 2007 , 34, 643-51	1.7	91	
46	Ovarian cancer: challenges of early detection. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 498-9		15	
45	Decline in use of hormone therapy among postmenopausal women in the United Kingdom. <i>Menopause</i> , 2007 , 14, 462-7	2.5	30	
44	Perceptions of colon cancer screening by stage of screening test adoption. <i>Cancer Nursing</i> , 2007 , 30, 178-85	2.6	27	
43	Feasibility of screening for ovarian cancer using symptoms as selection criteria. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2007 , 114, 59-64	3.7	25	
42	Surgical morbidity associated with radical trachelectomy and radical hysterectomy. <i>Gynecologic Oncology</i> , 2006 , 101, 450-4	4.9	84	
41	The value of ovarian cancer screening. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2006 , 67, 314-7	0.8	1	
40	Familial ovarian screeningeffective or ineffective?. <i>British Journal of Cancer</i> , 2006 , 95, 1124; author reply 1126-7	8.7	8	
39	Screening for gynaecological cancers. European Journal of Surgical Oncology, 2006, 32, 818-24	3.6	8	
38	Screening for ovarian cancer. Clinical Obstetrics and Gynecology, 2006, 49, 433-47	1.7	65	
37	Postmenopausal women undergoing transvaginal ultrasound screening prefer not to have chaperones. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2006 , 113, 954-7	3.7	9	
36	Epithelial ovarian cancer and induction of ovulation. <i>Reviews in Gynaecological Practice</i> , 2005 , 5, 131-1	38	4	

35	Development of a self-efficacy scale for mammography. Research in Nursing and Health, 2005, 28, 329-	362	99
34	New tumor markers: CA125 and beyond. <i>International Journal of Gynecological Cancer</i> , 2005 , 15 Suppl 3, 274-81	3.5	366
33	Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7919-26	2.2	190
32	Ovarian cancer screening. <i>Cmaj</i> , 2004 , 171, 323-4	3.5	19
31	Progress and challenges in screening for early detection of ovarian cancer. <i>Molecular and Cellular Proteomics</i> , 2004 , 3, 355-66	7.6	316
30	Screening for ovarian cancer. Reviews in Gynaecological Practice, 2004, 4, 156-161		
29	Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. <i>Journal of Clinical Oncology</i> , 2003 , 21, 206s-210s	2.2	177
28	Beliefs associated with fecal occult blood test and colonoscopy use at a worksite colon cancer screening program. <i>Journal of Occupational and Environmental Medicine</i> , 2003 , 45, 891-8	2	57
27	Management of women who test positive for high-risk types of human papillomavirus: the HART study. <i>Lancet, The</i> , 2003 , 362, 1871-6	40	416
26	Screening for ovarian cancer. Expert Review of Anticancer Therapy, 2003, 3, 55-62	3.5	13
25	CA125 and Other Tumor Markers in Screening and Monitoring of Ovarian Cancer 2003 , 193-200		1
24	Screening for familial ovarian cancer 2002 , 220-234		3
23	Screening for ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2002 , 16, 469-82	4.6	37
22	Ovarian cancer screening. British Journal of Hospital Medicine, 2002, 63, 210-3		8
21	Ovarian cancer screening in the general population: current status. <i>International Journal of Gynecological Cancer</i> , 2001 , 11 Suppl 1, 3-6	3.5	39
20	Ovarian cancer screening in the general population. <i>Current Opinion in Obstetrics and Gynecology</i> , 2001 , 13, 61-4	2.4	34
19	Factors influencing serum CA125II levels in healthy postmenopausal women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2001 , 10, 489-93	4	52
18	Recent developments in ovarian cancer screening. <i>Current Opinion in Obstetrics and Gynecology</i> , 2000 , 12, 39-42	2.4	81

LIST OF PUBLICATIONS

17	Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000 , 107, 1069-74	3.7	29
16	Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. <i>BJOG:</i> an International Journal of Obstetrics and Gynaecology, 2000 , 107, 165-9	3.7	48
15	Ovarian cancer screening in the general population. <i>Ultrasound in Obstetrics and Gynecology</i> , 2000 , 15, 350-3	5.8	21
14	Registration of ovarian cancer in England and Wales. <i>British Journal of Cancer</i> , 2000 , 83, 279-279	8.7	78
13	Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. <i>British Journal of Cancer</i> , 1999 , 80, 1644-7	8.7	46
12	A comparison of national cancer registry and direct follow-up in the ascertainment of ovarian cancer. <i>British Journal of Cancer</i> , 1999 , 80, 1826-7	8.7	11
11	Screening for ovarian cancer: a pilot randomised controlled trial. <i>Lancet, The</i> , 1999 , 353, 1207-10	40	447
10	Evaluation of plasma fructosamine as a screening test for gestational diabetes. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1991 , 31, 25-6	1.7	2
9	Ovarian Cancer Screening47-68		O
8	Screening for Ovarian Cancer144-150		
7	High Density Lipoprotein pathway as a therapeutic target for coronary heart disease: individual participant meta-analysis in 28,597 individuals with 4197 coronary events		2
6	Common variants in breast cancer risk loci predispose to distinct tumor subtypes		1
5	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1
4	A Comprehensive Epithelial Tubo-Ovarian Cancer Risk Prediction Model Incorporating Genetic and Epidemiological Risk Factors		2
3	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses		2
2	Serum markers for gynaecological cancer in the reproductive years155-178		

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma 1